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ABSTRACT
Introduction: Critically ill patients are at high risk of
nosocomial infections, with between 20% and 40% of
patients admitted to the intensive care unit (ICU)
acquiring infections. These infections result in increased
antibiotic use, and are associated with morbidity and
mortality. Although critical illness is classically associated
with hyperinflammation, the high rates of nosocomial
infection argue for an importance of effect of impaired
immunity. Our group recently demonstrated that a
combination of 3 measures of immune cell function
(namely neutrophil CD88, monocyte HLA-DR and %
regulatory T cells) identified a patient population with a
2.4–5-fold greater risk for susceptibility to nosocomial
infections.
Methods and analysis: This is a prospective,
observational study to determine whether previously
identified markers of susceptibility to nosocomial
infection can be validated in a multicentre population, as
well as testing several novel markers which may improve
the risk of nosocomial infection prediction. Blood samples
from critically ill patients (those admitted to the ICU for at
least 48 hours and requiring mechanical ventilation alone
or support of 2 or more organ systems) are taken and
undergo whole blood staining for a range of immune cell
surface markers. These samples undergo analysis on a
standardised flow cytometry platform. Patients are
followed up to determine whether they develop
nosocomial infection. Infections need to meet strict
prespecified criteria based on international guidelines;
where these criteria are not met, an adjudication panel of
experienced intensivists is asked to rule on the presence
of infection. Secondary outcomes will be death from
severe infection (sepsis) and change in organ failure.
Ethics and dissemination: Ethical approval including
the involvement of adults lacking capacity has been
obtained from respective English and Scottish Ethics
Committees. Results will be disseminated through
presentations at scientific meetings and publications in
peer-reviewed journals.
Trial registration number: NCT02186522; Pre-results.
INTRODUCTION
Critical illness increases the risk of nosoco-
mial infection, with between 20% and 40%
of patients admitted to the intensive care
unit (ICU) acquiring infections during their
critical care stay,1 2 a rate that approaches
that seen in haematopoietic stem cell trans-
plantation.3 Provision of organ support
requires the disruption of epithelial and
mucosal barrier innate immune system pro-
tection through the placement of devices
such as endotracheal tubes, urinary catheters
and central venous catheters. These infec-
tions are often bacterial and are associated
with increased antibiotic use.1 2 In addition
to bacterial infections, critically ill patients
are at risk of reactivation of latent viral infec-
tions.4 Therefore, it is thought that the com-
bination of immune vulnerability and
microbial colonisation is responsible for the
Strengths and limitations of this study
▪ Multi-site study recruiting from geographically
and clinically diverse populations.
▪ Multisite nature has produced a programme of
flow cytometry standardisation which we believe
to be both robust and reproducible and so sets
the scene for potential clinical use of these
assays should they prove to be of value.
▪ We have taken steps to try to minimise variability
in the diagnosis of infection, through the use of
rigid criteria and consensus review of cases
which do not meet these criteria.
▪ The weaknesses of this study are that it is obser-
vational, and thus will not be able to inform clini-
cians of what actions they should take in
response to these results should clinically
useable tests be developed.
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high rates of nosocomial infection seen in critically ill
patients.1
Critical illness resulting from trauma, sepsis and post-
surgical complications all have commonality in the
innate and adaptive immune responses.5 6 Many diseases
that can precipitate the need for exogenous organ
support and admission to intensive care are charac-
terised by a profound systemic inﬂammatory response,7
with associated immune cell activation8 and immune
system-mediated organ damage.9 However, it is now
increasingly apparent that this overexuberant inﬂamma-
tion is accompanied by an equally vigorous counter-
regulatory anti-inﬂammatory response.5 10 The appar-
ently maladaptive, complex immune dysfunction in crit-
ically ill patients manifests across a range of cellular
actions and functions, involving both the innate and
adaptive arms of the immune system.5 10–15 Defects have
been noted in neutrophils,11 monocytes,12 16 17 T lym-
phocytes10 13–15 and splenic dendritic cells.10 The recent
identiﬁcation of elevated proportions of regulatory
helper-T cells (Tregs) in sepsis14 15 is in keeping with the
supposition that much of the immunosuppression arises
from the overactivation of counter-regulatory mechan-
isms. In human and experimental sepsis, Tregs mediate
lymphocyte anergy and are associated with worse
outcomes.15
Rationale for the study
Although it seems plausible that the immune defects
found in critical illness are associated with an increased
risk of acquiring nosocomial infections, the concept that
immune cell abnormalities always precede nosocomial
infections, necessary for causality, is inconsistently
reported in the literature.14 16 Following our previous
study,11 which demonstrated the beneﬁts of combining
measures of immune dysfunction on predicting nosoco-
mial infection, there is a need to validate the markers in
a new cohort. Undertaking this as a multicentre study
will help develop standardised ﬂow cytometric measures
and improve the external validity of the markers that
predict risk of nosocomial infection. If a selected set of
immune abnormalities that could be modiﬁed with a
single intervention are present together, then develop-
ment of a test could stratify patients for risk of nosoco-
mial infections for targeted interventions.17 Finally,
identifying multiple cell defects/markers will help
design future trials of therapies and prophylactic mea-
sures to prevent nosocomial infections.
Hypotheses
1. Markers of neutrophil, monocyte and T-cell hypoac-
tivity will predict those critically ill patients who are at
risk of nosocomial infection.
2. These markers will have added predictive value when
combined.
3. Additional predictive ability will be achieved through
examination of monocyte and Treg subsets and other
cell surface markers of immune cell function.
Primary aims
1. To validate the ability of neutrophil CD88, monocyte
HLA-DR and percentage of Tregs to predict those
patients at risk of nosocomial infection.
2. To determine the optimal way of combining these
measures to risk stratify patients.
3. To develop a clinically useable test.
Secondary aims
1. To determine the relationship between the measures
outlined above and risk of death from sepsis.
2. To determine whether more detailed phenotyping of
monocyte and Treg subsets provides additional value
in predicting risk of nosocomial infection.
3. To explore whether other cell surface measures of
immune cell function and phenotype may predict
nosocomial infection.
METHODS AND ANALYSIS
This protocol outlines a multicentre, prospective observa-
tional study in which critically ill patients will be recruited
and assessments made of immune cell surface pheno-
typic markers at multiple time points. Patients will be fol-
lowed to determine outcomes of interest, the primary
outcome being development of nosocomial infection.
Study population
The population will be drawn from four UK adult ICUs,
consisting of:
1. Royal Inﬁrmary, Edinburgh (liver/general unit);
2. Western Inﬁrmary, Edinburgh (neurosciences/
general unit);
3. St Thomas’ Hospital, London (cardiac/general unit);
4. Sunderland Royal Hospital (general unit).
Consecutive patients will be eligible if they are aged
>16 (Scotland) or >18 (England), receiving support of
level 3 care (ie, requiring invasive support of respiratory
system alone, or two or more other organ systems (hae-
moﬁltration, inotropes/vasopressors)) and predicted to
remain in the ICU for at least 48 hours.
Exclusion criteria are not being expected to survive
for a further 24 hours, known or suspected ICU-acquired
infection at time of screening (non-ICU-acquired noso-
comial infection—ie, non-ICU healthcare-associated
infection is not an exclusion), known inborn errors of
immune function, immunosuppression (corticosteroids
up to 400 mg hydrocortisone equivalent daily dose per-
mitted), HIV infection, hepatitis B and C infection,
receiving extracorporeal membrane oxygenation, preg-
nancy and previously enrolment in the study.
Co-enrolment is permitted where the overall phlebot-
omy burden on patients is acceptable (<50 mL at any
one time point and total phlebotomy load of <150 mL),
where the co-enrolled study is deemed unlikely to affect
the primary end point of the ImmuNe FailurE in
Critical Therapy (INFECT) study and where a formal
coenrolment agreement is in place.
2 Conway Morris A, et al. BMJ Open 2016;6:e011326. doi:10.1136/bmjopen-2016-011326
Open Access
group.bmj.com on October 24, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
SAMPLING SCHEDULE
Blood samples for ﬂow cytometric analysis of surface
receptor expression will be taken on study enrolment,
and then on day 2 after study enrolment, and at 48-hour
intervals until day 12, a maximum of seven samples per
patient. Patients discharged from the ICU within the
16-day study window will have a maximum of two further
samples taken at 3–4-day intervals up to day 12 of the
study to minimise burden of venepuncture. Where pos-
sible, these will be collected at the time of routine vene-
puncture for clinical sampling. Patients will be followed
for the development of infection for 16 days (by this
time, the great majority of infections had been acquired
in the original study and few patients were left in the
ICU alive and without infection). All survivors who
remain in hospital will be followed to this point includ-
ing those who have left the ICU.
Clinical and demographic data will be collected
including age, sex, functional comorbidity index,
smoking status, physiological data (cute Physiology and
Chronic Health Evaluation score II (APACHE II) score
on admission, Sequential Organ Failure Assessment
(SOFA) score at baseline, full blood count and differen-
tial white cell count) and clinical data (admission diag-
nosis, admission source, antibiotics, invasive devices
present and duration). Similar clinical data will be col-
lected at each sample time point. Hospital outcome (ie,
discharged alive, died or transferred to another hos-
pital) will also be collected.
DEFINITION OF INFECTION
Infections will need to meet strict, predeﬁned criteria
(see online supplementary appendix A) and will be
assessed by research staff blinded to the immune pheno-
typing data. Suspected infections which do not meet the
criteria for conﬁrmed infection will be reviewed ‘ofﬂine’
by a panel of clinicians blinded to the immune pheno-
typing data using information from a prospectively col-
lected proforma. The outcomes from this will be ‘highly
likely’ infection and ‘unlikely infection/colonisation’
(colonisation being where microbes are grown in the
absence of evidence for infection). The day infection is
acquired will be deﬁned as the day the sample which
shows positive for microbiology was taken. In the case of
sterile cultures where the clinician strongly suspects
infection, the day of infection will be deﬁned as the day
strong clinical suspicion was raised. Therefore, outcomes
will be (1) ‘conﬁrmed’, (2) ‘probable infection’ and (3)
‘unlikely infection/colonisation’.
Patients who are transferred to a non-study hospital will
have data included up until the day of discharge and will
be followed up via telephone contact from the recording
unit to ascertain whether there were any conﬁrmed or
suspected infections in the days following transfer (up to
16 days poststudy entry). Patients transferred from one
participating site to another will remain in the study and
have data and samples collected as per study protocol.
FLOW CYTOMETRIC STANDARDISATION AND SAMPLE
STAINING
All sites have standardised on the same platform the
FACS Canto II (Becton Dickinson Biosciences, San Jose,
California, USA—from here on BDB) for ﬂow cytometric
analysis of samples. Machines will be standardised by
monthly matching of target values using a common batch
of Cytometry Setup and Tracking (CS&T) beads (BDB),
and daily internal quality control using CS&T beads.
Leucocyte cell surface staining will be conducted
using antibodies supplied by BDB. All sites use anti-
bodies from the same batch. Staining, data capture and
storage will be conducted in accordance with a single
study standard operating procedure.
Flow cytometry data will be held centrally. Final ana-
lysis will be conducted using a single analysis platform,
VenturiOne (Applied Cytometry, Shefﬁeld, UK).
CELLULAR IMMUNOPHENOTYPING
The primary measures are to validate our previous ﬁnd-
ings,11 namely: neutrophil CD88, monocyte HLA-DR and
percentage CD4 cells expressing the CD25+/CD127lo
regulatory phenotype, using the cut-offs deﬁned by our
previous study.11
Additional phenotypic measurements include neutro-
phil and monocyte activation markers (including CD11b,
CD66b, CD312), subtypes of regulatory T cells and Treg
activation, frequency of monocyte subsets and subset
HLA-DR expression, frequency of dendritic cell subtypes,
expression of monocyte and lymphocyte PD1 and PDL1,
frequency of granulocytic and monocytic myeloid-derived
suppressor cells, and frequency of B-cell subtypes.
SAMPLE SIZE
In a cohort studied previously,11 34% of patients were
conﬁrmed as having secondary sepsis. We therefore
expect the panel of markers to perform well when pre-
dicting 25–45% of patients to have secondary sepsis.
Across a broad range of possible positive predictive value
(PPV) performance (50–90%), the 95% CI width for
the PPV would range from ±5.5% to ±15.9%, indicating
moderately precise estimation of the PPV. Using a
similar rationale, we would expect the 95% CI width for
the negative predictive value (NPV) to range from
±4.3% to ±10.8%, indicating precise estimation of the
NPV. A conservative estimate of a 50% PPV with a 35%
rate of secondary sepsis would yield a 95% CI of 39–61%
in a cohort of 200 patients. We also intend to recruit 20
patients initially to conﬁrm that the reformulated ﬂow
cytometric tests match the performance of those from
the derivation cohort,11 and thus we propose recruiting
to a 220 patient cohort.
INFORMED CONSENT
Consent and assent procedures will be conducted under
the relevant legislation, in England (Mental Capacity
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Act, 2005) or Scotland (Adults with Incapacity
(Scotland) Act, 2000) for consent/assent of adults
without capacity. In England, assent is obtained, where
possible, following discussion with the patient’s next of
kin (personal consultee). Where a personal consultee is
unavailable, assent is provided by a professional con-
sultee, being a senior medical professional who is not in
the research team. In circumstances where next of kin
are unable to attend the ICU promptly, deferred
consent procedures are used.
In Scotland, the patient’s relative or welfare attorney
provides consent. If the patient’s relative or welfare attor-
ney is unable to attend the ICU, consent may be pro-
vided in a telephone conversation providing a second
member of staff witnesses the discussion.
Patients who recover capacity will be approached to
provide retrospective consent.
SAFETY OF PARTICIPANTS
The only safety concern is that of potential additional
venepuncture in patients; the risks of this are of minor
harm (bruising). Post-ICU sampling (where indwelling
lines are not present for blood sampling) is limited to a
maximum of two samples.
DATA ANALYSIS PLAN
A detailed statistical analysis plan will be ﬁnalised prior
to the locking of the study database.
Studies will be conducted to ensure that the ﬂow cyto-
metric readings of each marker are reproducible to
demonstrate they can be a useful test. Interobserver and
intraobserver reliability studies will be conducted with
three expert readers of the data. Fifty data ﬁles will be
read to determine interobserver agreement, with 13 ﬁles
for intraobserver agreement. After a preliminary reliabil-
ity study, an optimisation stage will occur with expert
meetings to further improve ﬂow cytometric gating strat-
egies in problematic markers to ensure that we do not
wrongly reject markers. A second reliability study will
then be conducted using the same sample size to select
markers taken forward to future stages of analysis.
The main analysis of the primary outcome will be an
analysis of the PPV and NPV of immune dysfunctions in
predicting nosocomial infection, as well as the predictive
ability of combinations of immune dysfunction. The
primary analysis will include both ‘conﬁrmed’ and ‘prob-
able’ infections as ‘infections’, with analysis by ‘con-
ﬁrmed’ infections only conducted as a sensitivity
analysis. Sensitivity and speciﬁcity will also be deter-
mined. Ninety-ﬁve per cent CIs will be calculated for all
measures of predictive accuracy.
As with the derivation cohort,6 ‘immune function/dys-
function’ will be deﬁned by the time point before ﬁrst
nosocomial infection occurs, censored for 2 days prior
to infection.
As a secondary analysis, a Cox model of time to acqui-
sition of infection will be ﬁtted, with the classiﬁcation
‘immune dysfunction’ or ‘no dysfunction’ as one inde-
pendent variable. The other independent variables will
be potential clinical confounders identiﬁed in previous
epidemiological work looking at risk factors for nosoco-
mial infection1 2 and will demonstrate whether our
novel tests add predictive value over routinely available
clinical and demographic data.
The association of immune dysfunctions with the sec-
ondary outcome measures ICU outcome (lived/died)
and death from sepsis (yes/no) will be assessed using
the same methods as the main analysis of the primary
outcome.
Determination of the clinical utility of the test will
come from a two-stage assessment. First, the reliability of
the ﬂow cytometric markers will be assessed, and
markers for clinical use must have excellent inter-rater
and intra-rater reliability. Second, the markers must be
clinically valuable, adding predictive ability beyond that
which can be gained from clinical assessment and stand-
ard laboratory parameters. Both these assessments are
inherent in the data analysis programme outlined above,
and will be reviewed both internally by the study consor-
tium and also by a group of key clinical stakeholders
who are independent of the study consortium.
Alongside this, a mocked-up clinical workﬂow will be
developed based on the laboratory procedures devel-
oped to run this study, using the experience of Becton
Dickinson’s established clinical assay systems.
ETHICS AND DISSEMINATION
Local research governance approval has been granted
by the three National Health Service (NHS) organisa-
tions covering the four sites where the study is being
conducted.
Study management
The study is managed by the Edinburgh Clinical Trials
Unit (ECTU) and the Edinburgh Critical Care Research
Group (ECCRG) at the University of Edinburgh,
Edinburgh, Scotland.
Sponsorship
The study is co-sponsored by the University of
Edinburgh and NHS Lothian.
Duration of study
The study was planned to run for 3 years, starting
October 2012, with initial assay development leading to
patient recruitment starting July 2014. Following success-
ful requests for grant extension due to delays in setting
up recruiting sites, the expected end date for recruit-
ment is 31 January 2016. Flow cytometric data will
require postacquisition processing prior to analysis; this
is expected to be completed by 1 April 2016. We expect
to have completed our primary data analysis with a view
to dissemination of results by August 2016, and at this
point we will consider the study complete.
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Results from the study will be reported according to
the Standards for Reporting of Diagnostic Accuracy
(STARD)18 guidelines for reporting diagnostic accuracy
studies and disseminated via presentations at scientiﬁc
meetings and publications in peer-reviewed journals.
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